Cadence announced positive results from a study assessing the impact of Ofirmev (acetaminophen) injection on certain healthcare-related outcomes in the perioperative setting.
Ofirmev is a proprietary intravenous formulation of acetaminophen indicated for the management of mild-to-moderate pain, the management of moderate-to-severe pain with adjunctive opioid analgesics, and the reduction of fever.
The study evaluated data from more than 22,000 inpatient admissions for major joint repair procedures from a hospital research database of >550 hospitals maintained by the Premier healthcare alliance from January 1, 2011 to November 30, 2012.
A total of 11,073 patients who underwent elective major joint arthroplasty and received Ofirmev on the day of surgery (cases) were matched to 11,073 patients who did not receive the treatment (controls) during their stay.
Data from two groups were analyzed for differences in adverse event (AE) incidence (captured through ICD-9 and DRG coding and rescue drug utilization), average hospital costs, and length of hospital stay
(LOS). In addition, the same endpoints were examined when 4 doses of IV acetaminophen were given instead of a single dose.
Among 3,578 matched patient pairs in total hip arthroplasty, AEs were lower with IV acetaminophen (24.5%) than with control (27.5%, P=0.001). IV acetaminophen use was associated with shorter mean
LOS (2.86 vs. 2.96 days, 2.4 hours difference, P<0.0001) and lower average costs ($16,890 vs. $17,275, $385 difference, P=0.02).
Among 8,055 matched patient pairs in total knee arthroplasty, AEs were lower with IV acetaminophen (24.7%) than with control (26.4%, P=0.007). IV acetaminophen use was associated with shorter mean LOS (3.01 vs. 3.10 days, 2.2 hours difference, p<0.0001) and lower average costs ($16,223 vs. $16,899, $675 difference, P<0.0001).
In addition, 4 doses of IV acetaminophen were associated with a shorter mean length of stay and lower average hospital costs as compared to a single dose.
For more information call (877) 647-2239 or visit Ofirmev.com.